Media headlines about Oncobiologics (NYSE:ONS) have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Oncobiologics earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.0671263679013 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of Oncobiologics (ONS) opened at $1.30 on Tuesday. Oncobiologics has a 52-week low of $0.78 and a 52-week high of $4.37.

Separately, Zacks Investment Research cut shares of Oncobiologics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.watchlistnews.com/oncobiologics-ons-earns-coverage-optimism-rating-of-0-07/1684277.html.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.

Insider Buying and Selling by Quarter for Oncobiologics (NYSE:ONS)

Receive News & Ratings for Oncobiologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.